本論文嘗試以放射治療結合腺病毒-IL3基因治療的方式對小鼠攝護腺癌 (TRAMP C-1) 進行治療，IL-3不但是調控幹細胞增生及分化成各型細胞的重要造血因子，也是癌症的免疫基因療法中可有效讓細胞毒性T細胞侵入腫瘤組織，引發毒殺腫瘤細胞免疫反應的重要因子，過去基因治療的相關實驗多是建立IL-3基因轉殖的腫瘤細胞來治療，耗時較久，若以腺病毒載體將IL-3基因帶入腫瘤細胞則更適合於臨床上的應用。雖然從受治療小鼠腫瘤生長曲線中看出放射治療結合腺病毒-IL3基因治療與單獨放射治療相比沒有明顯成效，但從RNA層面的RT-PCR結果可以得知是因為此款腺病毒載體引起的宿主免疫反應超過了IL3基因治療的效果所造成，可以改用其他類型的腺病毒載體來降低宿主免疫反應。
本論文另一主題是不同週齡攝護腺癌基因轉殖鼠 (TRAMP，transgenic adenocarcinoma of the mice prostate) 的基因表現與切片觀察，TRAMP轉殖鼠的轉殖基因段是以大鼠PB (probasin) 基因為啟動子，SV 40-Tag當致癌基因而製造出來的基因轉殖鼠，藉由RNA層面的RT-PCR結果可以看出TRAMP轉殖鼠的攝護腺及肺臟確實都攜帶SV 40-Tag致癌基因，而原本只應該在攝護腺組織才會表現的PB基因卻也能在肺臟裡找到。另一欲觀察的基因mSTEAP原本只特異表現於攝護腺、腎臟及睪丸，但卻在正常小鼠肺臟組織中也可發現，使用mSTEAP當攝護線治療目標的方式是否可行仍須再評估。而mTEM1基因應只會較高程度的表現於血管新生時的腫瘤中，但我們卻從RT-PCR結果可以看到TRAMP轉殖鼠連肺臟都有很大量的mTEM1表現。

TRAMP轉殖鼠攝護腺切片H & E stain的部分可明顯看出其攝護腺管體在癌化過程中上皮細胞增生的情況，細部觀察更可看出其細胞核逐漸變形，逐步邁向未分化完全的癌細胞及微指狀突起消失的現象。

The aim of this research is to combine radiation therapy and adenovirus-IL3 gene therapy for TRAMP C-1 prostate cancer. Interleukin 3 (IL-3) is known as a hematopoietic factor. Its function is not only to stimulate stem cell proliferation and differentiation, but is also able to stimulate cytotoxic T cell recognizing and killing cancer cells in the model of cancer immunogene therapy. Adenovirus vector is a useful vector to deliver genes into cancer cells in situ and is more practical for clinical application. This study showed that there was not significant difference between the group of combining radiation therapy and adenovirus-IL3 gene therapy and the group of radiation therapy only. The results of RT-PCR suggested that adenovirus vector induced stronger host immune response than IL-3 gene therapy. The choice of other vectors that do not elicit host immune response is suggested.
The second topic of this research is to study the histological changes and the pattern of gene expression profile in TRAMP mice (transgenic adenocarcinoma of the mice prostate) at different ages. RT-PCR results showed that both prostate and lung tissues expressed SV 40-Tag oncogene and probasin mRNAs. The mSTEAP gene should be expressed only in prostate, kidney and testis, but its expression was also found in lung tissue. mTEM1 gene should be expressed and up-regulated only in angiogenesis tumors. However, the result showed that mTEM1 was also highly expressed in lung tissue in TRAMP mice.

1. Cooke, R. Dr. Folkman's War:Angiogensis and the Struggle to
Defeat Cancer. Taipei: Random House Inc., 2001.
2. Hall, E. J. Direct and Indirect Action of Radiation
The Oxygen Effect. In: Radiobiology for the Radiologist,
Fifth edition, pp. 12-14, 91-95. Philadelphia, PA 19106 USA:
Lippincott Williams & Wilkins, 2000.
3. Chiocca, E. A. Oncolytic viruses. Nat Rev Cancer, 2: 938-
950, 2002.
4. Roelvink, P. W., Lizonova, A., Lee, J. G., Li, Y.,
Bergelson, J. M., Finberg, R. W., Brough, D. E., Kovesdi,
I., and Wickham, T. J. The coxsackievirus-adenovirus
receptor protein can function as a cellular attachment
protein for adenovirus serotypes from subgroups A, C, D, E,
and F. J Virol, 72: 7909-7915, 1998.
5. Wickham, T. J., Mathias, P., Cheresh, D. A., and Nemerow, G.
R. Integrins alpha v beta 3 and alpha v beta 5 promote
adenovirus internalization but not virus attachment. Cell,
73: 309-319, 1993.
6. Stone, D., David, A., Bolognani, F., Lowenstein, P. R., and
Castro, M. G. Viral vectors for gene delivery and gene
therapy within the endocrine system. Journal of
Endocrinology, 164: 103-118, 2000.
7. Levy, J. A., Fraenkel-Conrat, H., and Owens, R. A.
Adenoviruses. In: Virology, Third edition, pp. 185-192. New
Jersey 07632: Prentice-Hall, Inc., 1994.
8. Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R.
Characteristics of a human cell line transformed by DNA from
human adenovirus type 5. J Gen Virol, 36: 59-74, 1977.
9. Thomson, A. W. Interleukin-3. In: The Cytokine Handbook, pp.
103-118. North Yorkshire, Great Britain: Academic Press
Limited, 1992.
10. Lantz, C. S., Boesiger, J., Song, C. H., Mach, N.,
Kobayashi, T., Mulligan, R. C., Nawa, Y., Dranoff, G., and
Galli, S. J. Role for interleukin-3 in mast-cell and
basophil development and in immunity to parasites. Nature,
392: 90-93, 1998.
11. McBride, W. H., Dougherty, G. D., Wallis, A. E., Economou,
J. S., and Chiang, C. S. Interleukin-3 in gene therapy of
cancer. Folia Biol (Praha), 40: 62-73, 1994.
12. Palmiter, R. D., Brinster, R. L., Hammer, R. E., Trumbauer,
M. E., Rosenfeld, M. G., Birnberg, N. C., and Evans, R. M.
Dramatic growth of mice that develop from eggs
microinjected with metallothionein-growth hormone fusion
genes. Nature, 300: 611-615, 1982.
13. Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D.,
Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A.
A., Matusik, R. J., and Rosen, J. M. Prostate cancer in a
transgenic mouse. Proc Natl Acad Sci U S A, 92: 3439-3443,
1995.
14. Matuo, Y., Adams, P. S., Nishi, N., Yasumitsu, H., Crabb,
J. W., Matusik, R. J., and McKeehan, W. L. The androgen-
dependent rat prostate protein, probasin, is a heparin-
binding protein that co-purifies with heparin-binding
growth factor-1. In Vitro Cell Dev Biol, 25: 581-584, 1989.
15. DeCaprio, J. A., Ludlow, J. W., Figge, J., Shew, J. Y.,
Huang, C. M., Lee, W. H., Marsilio, E., Paucha, E., and
Livingston, D. M. SV40 large tumor antigen forms a specific
complex with the product of the retinoblastoma
susceptibility gene. Cell, 54: 275-283, 1988.
16. Oesterling, J. E. Prostate-specific antigen. Improving its
ability to diagnose early prostate cancer. Jama, 267: 2236-
2238, 1992.
17. Reiter, R. E., Gu, Z., Watabe, T., Thomas, G., Szigeti, K.,
Davis, E., Wahl, M., Nisitani, S., Yamashiro, J., Le Beau,
M. M., Loda, M., and Witte, O. N. Prostate stem cell
antigen: a cell surface marker overexpressed in prostate
cancer. Proc Natl Acad Sci U S A, 95: 1735-1740, 1998.
18. Israeli, R. S., Powell, C. T., Fair, W. R., and Heston, W.
D. Molecular cloning of a complementary DNA encoding a
prostate-specific membrane antigen. Cancer Res, 53: 227-
230, 1993.
19. Hubert, R. S., Vivanco, I., Chen, E., Rastegar, S., Leong,
K., Mitchell, S. C., Madraswala, R., Zhou, Y., Kuo, J.,
Raitano, A. B., Jakobovits, A., Saffran, D. C., and Afar,
D. E. STEAP: a prostate-specific cell-surface antigen
highly expressed in human prostate tumors. Proc Natl Acad
Sci U S A, 96: 14523-14528, 1999.
20. Bacich, D. J., Pinto, J. T., Tong, W. P., and Heston, W. D.
Cloning, expression, genomic localization, and enzymatic
activities of the mouse homolog of prostate-specific
membrane antigen/NAALADase/folate hydrolase. Mamm Genome,
12: 117-123, 2001.
21. Yang, D., Holt, G. E., Velders, M. P., Kwon, E. D., and
Kast, W. M. Murine six-transmembrane epithelial antigen of
the prostate, prostate stem cell antigen, and prostate-
specific membrane antigen: prostate-specific cell-surface
antigens highly expressed in prostate cancer of transgenic
adenocarcinoma mouse prostate mice. Cancer Res, 61: 5857-
5860, 2001.
22. Folkman, J. Tumor angiogenesis. Adv Cancer Res, 43: 175-
203, 1985.
23. Folkman, J. and Ingber, D. Inhibition of angiogenesis.
Semin Cancer Biol, 3: 89-96, 1992.
24. Carson-Walter, E. B., Watkins, D. N., Nanda, A.,
Vogelstein, B., Kinzler, K. W., and St Croix, B. Cell
surface tumor endothelial markers are conserved in mice and
humans. Cancer Res, 61: 6649-6655., 2001.
25. St Croix, B., Rago, C., Velculescu, V., Traverso, G.,
Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J.,
Lengauer, C., Vogelstein, B., and Kinzler, K. W. Genes
expressed in human tumor endothelium. Science, 289: 1197-
1202., 2000.
26. Williams, C. S., Mann, M., and DuBois, R. N. The role of
cyclooxygenases in inflammation, cancer, and development.
Oncogene, 18: 7908-7916, 1999.
27. Johnson, M. A., Hernandez, I., Wei, Y., and Greenberg, N.
Isolation and characterization of mouse probasin: An
androgen-regulated protein specifically expressed in the
differentiated prostate. Prostate, 43: 255-262., 2000.
28. Charles A. Janeway, J., Travers, P., Walport, M., and
Shlomchik, M. J. The Adaptive Immune Response. In: M.
Morales (ed.), Immunobiology, Fifth edition. New York, NY
10001-2299: Garland Publishing, 2001.
29. Gilroy, D. W., Colville-Nash, P. R., Willis, D., Chivers,
J., Paul-Clark, M. J., and Willoughby, D. A. Inducible
cyclooxygenase may have anti-inflammatory properties. Nat
Med, 5: 698-701, 1999.
30. Huss, W. J., Hanrahan, C. F., Barrios, R. J., Simons, J.
W., and Greenberg, N. M. Angiogenesis and prostate cancer:
identification of a molecular progression switch. Cancer
Res, 61: 2736-2743., 2001.